While abnormal signaling mediated through metabotropic glutamate receptor 5 (mGluR5) is involved in the pathophysiology of Autism Spectrum Disorder (ASD), Fragile X Syndrome and Tuberous Sclerosis, the role of other mGluRs and their associated signaling network genes in syndromic ASD is unknown. This study sought to determine whether mGluR Copy Number Variants (CNV's) were overrepresented in children with syndromic ASD and if mGluR "second hit" confers additional risk for ASD in 22q11.2 Deletion Syndrome (22q11DS). To determine whether mGluR network CNV'S are enriched in syndromic ASD, we examined microarrays from children with ASD (n = 539). Patient categorization (syndromic vs nonsyndromic) was done via blinded medical chart review in mGluR positive and randomly selected mGluR negative cases. 11.5% of ASD had mGluR CNV's vs. 3.2% in controls (p < 0.001). Syndromic ASD was more prevalent in children with mGluR CNVs (74% vs 16%, p < 0.001). A comparison cohort with 22q11DS (n = 25 with ASD, n = 50 without ASD), all haploinsufficient for mGluR network gene RANBP1, were evaluated for "second mGluR hits". 20% with 22q11.2DS + ASD had "second hits" in mGluR network genes vs 2% in 22q11.2DS-ASD (p < 0.014). We propose that altered RANBP1 expression may provide a mechanistic link for several seemingly unrelated genetic and environmental forms of ASD. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . In addition, prenatal exposure to thalidomide, valproic acid, misoprostol, ethanol and maternal rubella infection, have been associated with an elevated risk of ASD [14] [15] [16] [17] [18] [19] . The mechanism for the development of ASD in most forms of idiopathic and syndromic forms of ASD remains elusive. Recently, signaling through metabotropic glutamate receptor 5 (mGluR5) as linked to the mTOR pathway has been implicated in the development of ASD in FXS and TS 20 . In FXS, abnormal production of Fragile X Mental Retardation Protein (FMRP) removes normal inhibition of signaling through the mGluR pathway. Tuberous Sclerosis leads to over-inhibition of signaling. Auerbach and colleagues demonstrated abnormal synaptic learning and atypical behavior in mouse models of FXS and TS, and reversed these effects by breeding the two strains together -mice harboring both mutations had normal mGluR signaling, and learning and behavior that was indistinguishable from control mice 20 . Other studies have demonstrated normalization of learning and behavior in Fragile X mice by administration of an mGluR5 antagonist 21, 22 . In addition to elucidating the mechanism for cognitive and behavioral differences in FXS and TS, these studies suggest a promising avenue for pharmacological treatment.
Autism Spectrum Disorder (ASD) occurs in approximately 1/88 individuals and is characterized by impairment in social communication and repetitive interests and activities 1 . Approximately 20% of cases occur in the context of an identifiable syndrome 2 . Genetic syndromes with ASD are heterogeneous, including cytogenetically visible chromosomal alterations (e.g. Trisomy 21), microdeletion and microduplication syndromes (e.g. 22q11.2 deletion syndrome [22q11.2DS]); and monogenic disorders (e.g. Fragile X Syndrome [FXS] , Tuberous Sclerosis [TS]) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . In addition, prenatal exposure to thalidomide, valproic acid, misoprostol, ethanol and maternal rubella infection, have been associated with an elevated risk of ASD [14] [15] [16] [17] [18] [19] . The mechanism for the development of ASD in most forms of idiopathic and syndromic forms of ASD remains elusive. Recently, signaling through metabotropic glutamate receptor 5 (mGluR5) as linked to the mTOR pathway has been implicated in the development of ASD in FXS and TS 20 . In FXS, abnormal production of Fragile X Mental Retardation Protein (FMRP) removes normal inhibition of signaling through the mGluR pathway. Tuberous Sclerosis leads to over-inhibition of signaling. Auerbach and colleagues demonstrated abnormal synaptic learning and atypical behavior in mouse models of FXS and TS, and reversed these effects by breeding the two strains together -mice harboring both mutations had normal mGluR signaling, and learning and behavior that was indistinguishable from control mice 20 . Other studies have demonstrated normalization of learning and behavior in Fragile X mice by administration of an mGluR5 antagonist 21, 22 . In addition to elucidating the mechanism for cognitive and behavioral differences in FXS and TS, these studies suggest a promising avenue for pharmacological treatment.
Evidence from recent human studies and animal models suggest that syndromic forms of ASD have behavioral overlap with idiopathic ASD but that there are identifiable behavioral signatures in each disorder 23 .
. An identifiable behavioral profile was present within each syndrome for those who met and did not meet criteria for ASD, suggesting a spectrum of severity rather than subgroups of patients with and without ASD in each group. The behavioral signature of children with idiopathic ASD was most similar to children with Tuberous Sclerosis, which the authors propose is due to convergence of many forms of ASD on the mTOR pathway.
Our group recently demonstrated that CNVs in the mGluR gene network (over 270 genes) occur more frequently in children with ASD than in controls 24 . Other recent studies have proposed that phenotypic differences might be seen in children harboring mutations affecting genes associated with the mGluR gene network, including those with identifiable syndromes 23, 25 . One limitation of these prior studies is that careful identification of children who may be more likely to have a syndromic form of ASD is limited. Approximately 20% of children with ASD are suspected to have an underlying genetic syndrome 2 . For this reason, the American College of Medical Genetics recommends that all children with an ASD receive a genome-wide microarray and undergo an evaluation by a clinical geneticist. However, to this date, only a small fraction of children with ASD have been evaluated by a clinical geneticist. Among our patient population through the Center for Autism Research, chart review of over 500 children with ASD evaluated by the center revealed that less than 10% had received any prior genetic testing (data not shown). In addition, as many disparate CNVs, distinct genetic syndromes and environmental exposure syndromes have an elevated rate of ASD in addition to birth defects. Birth defects are not reported to be more frequent in children with idiopathic ASD. In this way, the presence of birth defects with ASD may be a marker that identifies children with a syndromic form of ASD that has yet to be clinically recognized.
For this reason, this study sought to closely investigate whether children with ASD identified to have mGluR CNVs would have features suggestive of Syndromic ASD (e.g. birth defects) at a higher rate than children with ASD and no mGluR network CNVs. Further, to investigate the role of mGluR network CNVs in the development of ASD in vulnerable syndromes, we studied children with 22q11.2 Deletion Syndrome, who all have deletion of the mGluR gene RANBP1. We identified children with 22q11.2DS (n = 75), including those with ASD (n = 25) and without ASD (n = 50), and looked for the rate of "second hits" in the mGluR network to determine if additional disease risk is incurred for ASD with double "hits" to the mGluR network.
Results

Syndromic features common in children with ASD with mGluR CNVs. We focused our analysis on
CNVs in the mGluR gene signaling network previously shown to be enriched in ASD (for detailed description of justification and methods see Hadley et al. 24 ). Children with ASD and mGluR CNVs were more likely to have syndromic features (e.g. birth defects, documentation of suspicion for genetic disorder based on dysmorphic features or uncommon medical problems, or clinical diagnosis of genetic syndrome) than children with ASD without mGluR CNVs (74% of mGluR + classified as "Syndromic" vs. 16% of mGluR -ASD; p < 0.0001). See Fig. 1 . Many of the mGluR CNVs in patients with syndromic ASD were included in larger clinically significant CNVs, but others occurred in smaller deleted or duplicated regions comparable in size to CNV's in the mGluR-group (See supplementary table 1). As mGluR network genes are present in the 22q11.2 region (RANBP1) and on chromosome 21 (APP GRIK1 MX1 PCBP3 SETD4), patients with ASD in the presence of 22q11.2DS, 22q11.2DupS or Trisomy 21 accounted for approximately one third of the patients with Syndromic ASD + mGluR network changes. The remainder of observed cytogenetic changes had individual non-overlapping deletions or duplications. As a second analytic step, all patients with very large deletions or duplications were excluded, and the mGluR+ and mGluR-groups were matched for overall CNV size and burdon. Comparison test for CNV number and burdon was Student's T-test, two tailed, with nonequivalent variances. Although there was no significant residual difference in the CNV size (p = 0.18) or numbers (p = 0.11) between the mGluR+ and mGluR− groups, there was a highly significant difference in the presence of syndromic features between the mGluR+ and mGluR− groups (p < 0.0001).
Second hit in mGluR gene network associated with increased risk of ASD in 22q11.2 Deletion Syndrome. As a comparison cohort, data from children with 22q11.2DS with ASD (n = 25) and without ASD (n = 50) who had completed high density microarray evaluation (either Affymetrix 6.0, Illumina HH550K, and Illumina 610Q) and clinical developmental assessments (as enrolled through a parallel study, approved by the Children's Hospital of Philadelphia Institutional Review Board, IRB 07-005352) were examined for the presence of a second mGluR network hit outside of the 22q11.2 region, using the same protocol as in Hadley et al. (2014) . This ensured that the same criteria were used to identify an mGluR CNV in the ASD group and in the second cohort of children with 22q11.2DS. "Second hits", deletions or duplications of an mGluR network gene outside of the 22q11.2 region, were found in 20% (5/25) of patients with ASD and only 2% (1/50) without ASD (p < 0.014). For complete list of second hits, see Table 1 .
Discussion
Prior studies have demonstrated that abnormal signaling (either too much or too little) through mGluR5 could be the basis for abnormal neural development (and possibly ASD) in FXS and TS. Our data suggest that derangement of the mGluR network may be responsible for increased rates of ASD seen in cytogenetically distinct forms of syndromic ASD. mGluR network genes are found in the 22q11.2 region as well as on Chromosome 21, which may be involved in the increased prevalence of ASD in both Down Syndrome and 22q11.2DS. However, all patients with Trisomy 21 or 22q11.2DS harbor the change in the mGluR network suggesting a second hit outside of the region may be necessary for expression of the ASD phenotype. Here, we demonstrate second hits as (Table 1) 27-30 . ASD occurs in approximately 20%, and psychosis in approximately 25% 5, 9, 27, 28, 30 . For this study we chose 22q11.2DS as a population for second hit evaluation for several reasons: 1) The authors are involved in a parallel study focusing on neurodevelopmental outcomes in children with 22q11.2 related disorders has ensured that there is thorough documentation of developmental assessments, which have all been done by a small group of developmental pediatricians and psychologists skilled in the diagnosis of ASD, making us confident in the designations of ASD and no ASD for our analysis; 2) Our hospital has a large 22q11.2 clinic that has served over 1,000 patients with 22q11.2 related disorders, so all providers are skilled in the recognition and treatment of 22q11.2 associated medical and developmental issues; 3) Individuals with 22q11.2DS typically have normal intelligence or mild intellectual disability, making their assessments for ASD less challenging than Trisomy 21, in which more profound intellectual disability is the norm; 4) The rate of ASD is high enough that we were able to confidently select 50 patients with documentation of no concerns for ASD and 25 patients with diagnoses of ASD by an experienced examiner. The genetic cause for ASD within the 22q11.2 region is unknown. We hypothesize in this study that the risk may be due to a combination of haploinsufficiency in the mGluR associated gene, RANBP1, together with second hits in the mGluR network for a portion of patients Figure 1 . Schematic of study design. Children with ASD and gene changes in mGluR network (mGluR + ASD) were more likely to have Syndromic ASD compared to children with ASD without abnormalities of mGluR network genes (mGluR -ASD). p < 0.0001. This remained significant after limiting the analysis to patients in the mGluR+ and mGlurR-groups with comparable overall size and number of CNV's (p < 0.0001). with 22q11.2DS. It is possible that second hits in additional gene networks that were not evaluated as part of this study also have a role in the development of ASD in 22q11.2DS. In order to further understand whether RANBP1 could play a role in the development of ASD in 22q11.2DS, we examined data from animal models, in vitro studies and human teratogenic exposures in which a high rate of ASD has been described. Paronett et al. 26 recently reported the first animal model of Ranbp1 (− /− ) mice. These mice had abnormal cortical development, including decreases in cortical thickness and number of neurons. This is particularly important because the 22q11.2 region contains approximately 40 genes, and this finding implicates Ranbp1 in brain development.
Based on our group's prior work 24 as well as the present study, we hypothesized that haploinsufficiency of the mGluR network gene in the 22q11.2 region, RANBP1, could confer risk for ASD in 22q11.2DS. Of note, five environmental agents have been shown to increase the rate of ASD with prenatal exposure, including thalidomide and valproic acid, which have been linked to the mGluR network or RANBP1 26, 31, [33] [34] [35] [36] [37] . Meganathan and colleagues hypothesized thalidomide embryopathy was mediated via effects of RANPB1 using a human embryonic stem cell model 32 . Supposing that ASD in thalidomide embryopathy and fetal valproate syndrome could be linked to a common mechanism with 22q11.2DS, a similar pattern of birth defects would be anticipated. A supplementary table lists the published birth defects in thalidomide embryopathy and fetal valproate syndrome compared to our patient cohort with 22q11.2DS. Every birth defect seen in either thalidomide embryopathy or fetal valproate syndrome has been observed in our cohort of patients with 22q11.2DS. Additional medical conditions are present in 22q11.2DS, which includes deletion of dozens of genes not hypothesized to be affected by exposure to thalidomide or valproate.
In the present study we found derangement of genes in the mGluR network at a high rate in patients with different forms of Syndromic ASD, including 22q11.2DS, Trisomy 21 and a large number of other seemingly-unrelated chromosomal alterations. Moreover, among children with 22q11.2DS, the presence of a "second hit" in the mGluR network was identified in 20% of children with ASD, and only 2% of those without ASD (p < 0.014). In children with 22q11.2DS, there was decreased expression in RANBP1 (data not shown).
Taken together, these data suggest that dysregulation of the mGluR network is a possible permissive factor that increases the propensity to develop an ASD. The striking increase in prevalence of ASD with a CNV affecting a second gene in the network suggests perturbations of mGluR signaling at multiple points is necessary. It is important to note that CNVs may only represent a fraction of changes in mGluR network genes, as this study did not include assessment of sequence variations, and these findings may therefore represent the "tip of the iceberg". While perturbation of the mGluR network appears to confer risk of ASD, additional genetic or environmental stressors are likely necessary for an individual child to develop ASD.
Striking similarities exist in the profiles of birth defects and elevated rates of Autism Spectrum Disorder seen in 22q11.2 Deletion Syndrome, Fetal Valproate Syndrome and Thalidomide Embryopathy. As thalidomide and VPA both cause decreased expression of RANBP1 mRNA, mimicking haploinsufficiency of the gene in 22q11.2 Deletion Syndrome, it is plausible that it could be involved in the common teratogenic profile across syndromes. Moreover, results from a Ranbp1 knockout mouse model from Paronett et al. 26 are also supportive of our hypothesis of the importance of RANBP1in the neurological consequences of 22q11.2DS and prenatal exposures affecting expression of RANBP1. In these studies, Ranbp1 (− /− ) homozygotes, proliferation of the basal progenitor pool in the cortex is disrupted, leading to a dramatic reduction in cortical thickness and substantially fewer neurons in the perinatal cortex. The changes resulting from loss of RANBP1 function parallel that seen in mice with the larger 22q11.2 Deletion, suggesting that haploinsufficiency of Ranbp1 may contribute to the disruption of cortical circuitry in 22q11DS. Future studies, addressing the neurodevelopmental phenotype of mice with haploinsufficiency of Ranbp1 are anticipated to help elucidate the mechanism by which alterations of the mGluR pathway leads to increased risk of ASD.
Methods
Participants.
Phenotypic data for patients with ASD as reported on parental health questionnaires from our biorepository (n = 6452), which includes samples from inside and outside our institution, were evaluated to identify patients who received clinical assessment at the Children's Hospital of Philadelphia and agreed to Electronic Health Record chart review. Medical records were available for 539 of these patients. Children were recruited for inclusion in the general Center for Applied Genomics biorepository when they were getting blood drawn for another purpose at The Children's Hospital of Philadelphia, so there is an overrepresentation of children with at least one medical problem in this patient cohort. DNA from 539 ASD cases were selected for further phenotypic and genotypic analysis. The parents of all patients gave informed consent for participation in the study, which was performed in accordance with relevant guidelines and regulations approved by the Institutional Review Board at the Children's Hospital of Philadelphia (IRB 06-004886).
Chart review. Subject selection and randomization process: All patients with an mGluR CNV (n = 62) and 100 patients without mGluR CNV were randomly selected for chart review. This procedure was selected to ensure that all patients with mGluR CNV received detailed chart review with an adequately sized comparison cohort. A three step process was done to ensure blinded chart review. The selection of the 162 charts was done by a geneticist with access to CNV data but without access to the Electronic Health Record (CK). Another author who had no access to CNV data nor the Electronic Health Record blinded and randomized the patient ID's (RTS). Finally, a physician with access to the Electronic Health Record but blinded to mGluR status (TLW) reviewed charts for documentation of ASD diagnosis and presence of other medical comorbidities.
Medical chart review. ASD: Charts were reviewed to confirm a diagnosis of ASD and also to determine medical comorbidities for each patient. Diagnosis of ASD was confirmed in the chart, but as this was a retrospective chart review, gold-standard research instruments (e.g. Autism Diagnostic Interview; Autism Diagnostic Observation Schedule) were not always available for review, while both parental intake surveys and Electronic Medical Records from the Children's Hospital of Philadelphia referenced ASD evaluations. Patient categorization of "Syndromic" vs "Nonsyndromic" ASD was based on the presence of additional birth defects and documentation of dysmorphic features in the medical record. For complete description of this process, see online supplemental methods.
Genotyping and CNVs.
A brief description of methods for CNV calling is included in supplemental online material. For a more detailed justification and description of methods related to CNV identification and list of genes included in mGluR network, please refer to Hadley et al (2014) 24 .
